HealthDay News – COVID-19 patients with hypertension have increased mortality risk, with significantly higher risk among those without antihypertensive treatment, according to a study published online June 4 in the European Heart Journal.

Chao Gao, from Xijing Hospital in Xi’an, China, and colleagues conducted a retrospective study of patients with COVID-19 admitted to Huo Shen Shan Hospital in Wuhan, China, to examine whether hypertension treatment influences mortality.

The researchers found that 29.5% of the 2877 hospitalized patients had a history of hypertension. Patients with hypertension had a significantly increased relative risk for mortality compared with those without hypertension after adjustment for confounders (adjusted hazard ratio [HR], 2.12; 95% confidence interval [CI], 1.17 to 3.82; P =.013). A significantly higher risk for mortality was seen among patients with a history of hypertension but without antihypertensive treatment compared with those with antihypertensive treatments (HR, 2.17; 95% CI, 1.03 to 4.57; P =.041). Mortality rates were similar for those receiving a renin-angiotensin-aldosterone system (RAAS) inhibitor and non-RAAS inhibitor (HR, 0.85; 95% CI, 0.28 to 2.58; P =.774). In a meta-analysis of 4 studies, patients with RAAS inhibitor use tended to have a reduced mortality risk (relative risk, 0.65; 95% CI, 0.45 to 0.94; P =.02).

Related Articles

“Due to the observational nature of the study, the results should be interpreted cautiously and considered as no obvious additional risk to continue RAAS inhibitors in patients with COVID-19 infection,” the authors write.

Abstract/Full Text

Editorial